SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-24-006099
Filing Date
2024-02-29
Accepted
2024-02-29 16:16:09
Documents
17
Period of Report
2024-02-29
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K pbyi20240227_8k.htm   iXBRL 8-K 25431
2 EXHIBIT 99.1 ex_632476.htm EX-99.1 211785
7 logo.jpg GRAPHIC 3258
  Complete submission text file 0001437749-24-006099.txt   391065

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA pbyi-20240229.xsd EX-101.SCH 3409
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE pbyi-20240229_def.xml EX-101.DEF 11424
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE pbyi-20240229_lab.xml EX-101.LAB 15310
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pbyi-20240229_pre.xml EX-101.PRE 11584
18 EXTRACTED XBRL INSTANCE DOCUMENT pbyi20240227_8k_htm.xml XML 2846
Mailing Address 10880 WILSHIRE BLVD. SUITE 2150 LOS ANGELES CA 90024
Business Address 10880 WILSHIRE BLVD. SUITE 2150 LOS ANGELES CA 90024 (424) 248-6500
PUMA BIOTECHNOLOGY, INC. (Filer) CIK: 0001401667 (see all company filings)

IRS No.: 770683487 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35703 | Film No.: 24703867
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)